RxDoctor Payments Data

Richard Lautzenheiser

Rheumatology · Indianapolis, INNPI 1609852227

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.1%), speaking fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Amgen at 57.1% of the total. Reporting peaked in 2019 at $5,205 and has fallen 97.7% since, to $122 in 2025.

$6,215in general payments, 2019–2025

Across 141 payments — averaging $44.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$807
  • Novartis$401
  • Mallinckrodt Hospital Products Inc.$198
  • Pfizer$191
  • Lilly USA, LLC$178
  • plus $889 from 16 others

What the payments were for

  • Speaking & faculty fees$2,70043%
  • Food & beverage$3,42655%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,215 in reported general payments places this provider in the 65th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Other rheumatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →